Valuation: Exagen Inc.

Market Cap 159M 138M 129M 118M 223M 15.17B 226M 1.51B 594M 7.58B 598M 585M 25.22B P/E 2026 *
-10.1x
P/E 2027 * -13x
Enterprise Value 159M 138M 129M 118M 223M 15.17B 226M 1.51B 594M 7.58B 598M 585M 25.22B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 1.96x
Free-Float
57.96%
Yield 2026 *
-
Yield 2027 * -
1 day+2.20%
1 week+48.12%
Current month+48.12%
1 month+39.79%
3 months+128.23%
6 months+99.11%
Current year+10.36%
1 week 4.54
Extreme 4.54
7.1
1 month 4.05
Extreme 4.05
7.1
Current year 2.59
Extreme 2.59
7.1
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.9
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 17/10/2022
Director of Finance/CFO 57 01/09/2024
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Chairman 72 19/01/2023
Director/Board Member 63 30/07/2019
Director/Board Member 56 17/06/2021
Date Insider Type Main position Quantity % Market Cap.
24/02/26 Sell

Chief Executive Officer

11,430 0.0504%
24/02/26 Sell

Chief Financial Officer

1,584 0.0070%
16/10/25 Sell

Chief Executive Officer

31,787 0.1445%
Change 5-day change 1-year change 3-year change Capi.($)
+2.20%+48.12%-25.36%+145.79% 159M
+17.75%+18.67%+125.23%+522.80% 38.01B
+0.52%+2.95%+22.45%+48.47% 25.67B
+0.04%-1.11%-20.34%-34.75% 7.73B
+3.04%+10.01%+33.57%+107.83% 5.36B
+0.19%+1.39%+20.23%+62.71% 3.38B
+6.77%+13.38%-30.33%+1,003.44% 2.08B
+4.27%+5.72%+180.64%+2.31% 2B
+0.83%+3.28%-8.58%-59.03% 1.92B
+3.62%+24.66%+26.53%-12.53% 1.78B
Average +3.94%+6.24%+32.41%+178.71% 8.81B
Weighted average by Cap. +8.42%+0.14%+65.30%+268.06%

Financials

2026 *2027 *
Net sales 73.89M 64.12M 60.04M 54.92M 104M 7.04B 105M 702M 276M 3.52B 277M 271M 11.71B 81.28M 70.53M 66.04M 60.41M 114M 7.74B 116M 773M 303M 3.87B 305M 299M 12.88B
Net income -15.83M -13.74M -12.87M -11.77M -22.22M -1.51B -22.51M -151M -59.07M -754M -59.45M -58.16M -2.51B -12.48M -10.83M -10.14M -9.28M -17.52M -1.19B -17.75M -119M -46.57M -594M -46.87M -45.85M -1.98B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
07/08/26 $6.710 +1.82% 101,433
06/08/26 $6.590 -0.90% 397,623
05/08/26 $6.650 +3.10% 1,222,724
04/08/26 $6.450 +37.82% 2,745,988
03/08/26 $4.680 +3.31% 212,105
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.590USD
Average target price
9.857USD
Spread / Average Target
+49.58%

Quarterly revenue - Rate of surprise